ARVN - アルビナス (Arvinas Inc.) アルビナス

 ARVNのチャート


 ARVNの企業情報

symbol ARVN
会社名 Arvinas Inc (アルビナス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アルヴィーナス(Arvinas Inc.)(旧名: Arvinas Holding Co LLC)は開発段階のバイオ医薬品会社である。同社は、疾患を引き起こすタンパク質を分解する治療法の開発と商品化に従事する。同社は病気を引き起こすタンパク質を選択的かつ効率的に分解・除去するために、身体の天然タンパク質処理システムを利用するように設計されたタンパク質分解誘導キメラ分子(PROTACs)を処理する技術プラットフォームを使用する。同社はPROTACプラットフォームを使用して、臓器系および組織における疾患を標的とするタンパク質分解産物候補パイプラインを構築する。同社はまたARV-110とARV-471のリード製品候補を第1相臨床試験に進めることにも注力する。同社は転移性去勢抵抗性前立腺癌(mCRPC)を有する男性にあるARV-110の第 I 相臨床試験、転移性エストロゲン受容体陽性(ER)とHER2陰性乳癌、またはER +陽性乳癌の女性におけるARV-471の第1相臨床試験を開始する予定である。   アルビナスは米国のバイオ薬品会社。がんをはじめとする治療困難な疾患を引き起こすタンパク質を分解し、除去するタンパク質分解剤の開発・研究を行う。特にアンドロゲン受容体およびエストロゲン受容体を含む前立腺がんや乳がんなどのがんに対して有効性のある分解薬の開発に焦点を当てる。本社所在地はコネチカット州ニュ―ヘブン。   Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
本社所在地 5 Science Park 395 Winchester Avenue New Haven CT 06511 USA
代表者氏名
代表者役職名
電話番号 +1 203-535-1456
設立年月日 41306
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 72人
url www.arvinas.com
nasdaq_url https://www.nasdaq.com/symbol/arvn
adr_tso
EBITDA EBITDA(百万ドル) -24.04163
終値(lastsale) 14.99
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 951.25580
売上高 売上高(百万ドル) 11.74966
企業価値(EV) 企業価値(EV)(百万ドル) 154.54711
当期純利益 当期純利益(百万ドル) -114.01680
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arvinas Inc revenues increased from $3.3M to $7.5M. Net loss applicable to common stockholders increased from $12.9M to $98.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 17% to $17.5M (expense) General and administrative increase of 88% to $2.8M (expense).

 ARVNのテクニカル分析


 ARVNのニュース

   Arvinas Appoints Linda Bain to its Board of Directors | MarketScreener  2020/06/11 11:01:04 MarketScreener
NEW HAVEN, Conn., June 11, 2020 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Linda Bain… | June 11, 2020
   Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why  2020/06/05 16:00:06 Zacks Investment Research
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
   How Arvinas (ARVN) Stock Stands Out in a Strong Industry  2020/05/12 12:54:00 Zacks Investment Research
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Arvinas, Inc. (ARVN) Upgraded to Buy: Here's What You Should Know  2020/05/05 16:00:06 Zacks Investment Research
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Arvinas Appoints Linda Bain to its Board of Directors | MarketScreener  2020/06/11 11:01:04 MarketScreener
NEW HAVEN, Conn., June 11, 2020 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Linda Bain… | June 11, 2020
   Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why  2020/06/05 16:00:06 Zacks Investment Research
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
   How Arvinas (ARVN) Stock Stands Out in a Strong Industry  2020/05/12 12:54:00 Zacks Investment Research
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Arvinas, Inc. (ARVN) Upgraded to Buy: Here's What You Should Know  2020/05/05 16:00:06 Zacks Investment Research
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Arvinas Appoints Linda Bain to its Board of Directors | MarketScreener  2020/06/11 11:01:04 MarketScreener
NEW HAVEN, Conn., June 11, 2020 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Linda Bain… | June 11, 2020
   Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why  2020/06/05 16:00:06 Zacks Investment Research
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
   How Arvinas (ARVN) Stock Stands Out in a Strong Industry  2020/05/12 12:54:00 Zacks Investment Research
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Arvinas, Inc. (ARVN) Upgraded to Buy: Here's What You Should Know  2020/05/05 16:00:06 Zacks Investment Research
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

 関連キーワード  (医薬品 米国株 アルビナス ARVN Arvinas Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)